Do analysts prefer BTCY or MBAI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biotricity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Check-Cap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is BTCY or MBAI more profitable?

Check-Cap has a net margin of 0.00% compared to Biotricity's net margin of -80.42%. Company Net Margins Return on Equity Return on Assets Biotricity -80.42% N/A -188.47% Check-Cap N/A N/A N/A

Do analysts rate BTCY or NDRA?

ENDRA Life Sciences has a consensus price target of $25.00, indicating a potential upside of 399.00%. Given ENDRA Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe ENDRA Life Sciences is more favorable than Biotricity. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biotricity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 ENDRA Life Sciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts rate NVNO or BTCY?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score enVVeno Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 Biotricity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer BTCY or ICCM?

IceCure Medical has a consensus price target of $52.50, indicating a potential upside of 2,182.61%. Given IceCure Medical's stronger consensus rating and higher probable upside, analysts clearly believe IceCure Medical is more favorable than Biotricity. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biotricity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 IceCure Medical 2 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.20

Is BTCY or ICCM more profitable?

Biotricity has a net margin of -80.42% compared to IceCure Medical's net margin of -427.67%. Biotricity's return on equity of 0.00% beat IceCure Medical's return on equity. Company Net Margins Return on Equity Return on Assets Biotricity -80.42% N/A -188.47% IceCure Medical -427.67% -174.26% -112.58%

Do analysts prefer INBS or BTCY?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intelligent Bio Solutions 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Biotricity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Biotricity (BTCY) Competitors

$0.12 0.00 (0.00%)

As of 08/28/2026 11:49 AM Eastern

Compare

BTCY vs. MBAI, NDRA, NVNO, ICCM, and INBS

Should you buy Biotricity stock or one of its competitors? Biotricity's main competitors and comparable companies include Check-Cap (MBAI), ENDRA Life Sciences (NDRA), enVVeno Medical (NVNO), IceCure Medical (ICCM), and Intelligent Bio Solutions (INBS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Biotricity compare to Check-Cap?

Biotricity (NASDAQ:BTCY) and Check-Cap (NASDAQ:MBAI) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biotricity	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Check-Cap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Check-Cap had 5 more articles in the media than Biotricity. MarketBeat recorded 5 mentions for Check-Cap and 0 mentions for Biotricity. Check-Cap's average media sentiment score of 0.57 beat Biotricity's score of 0.00 indicating that Check-Cap is being referred to more favorably in the news media.

Company	Overall Sentiment
Biotricity	Neutral
Check-Cap	Positive

Biotricity has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market. Comparatively, Check-Cap has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market.

Check-Cap has lower revenue, but higher earnings than Biotricity. Biotricity is trading at a lower price-to-earnings ratio than Check-Cap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biotricity	$12.06M	0.21	-$14.09M	-$0.14	N/A
Check-Cap	N/A	N/A	$4.14M	-$14.07	N/A

Check-Cap has a net margin of 0.00% compared to Biotricity's net margin of -80.42%.

Company	Net Margins	Return on Equity	Return on Assets
Biotricity	-80.42%	N/A	-188.47%
Check-Cap	N/A	N/A	N/A

3.9% of Biotricity shares are owned by institutional investors. Comparatively, 1.1% of Check-Cap shares are owned by institutional investors. 1.6% of Biotricity shares are owned by company insiders. Comparatively, 0.5% of Check-Cap shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Biotricity and Check-Cap tied by winning 6 of the 12 factors compared between the two stocks.

How does Biotricity compare to ENDRA Life Sciences?

Biotricity (NASDAQ:BTCY) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations.

ENDRA Life Sciences has a consensus price target of $25.00, indicating a potential upside of 399.00%. Given ENDRA Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe ENDRA Life Sciences is more favorable than Biotricity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biotricity	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
ENDRA Life Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, ENDRA Life Sciences had 1 more articles in the media than Biotricity. MarketBeat recorded 1 mentions for ENDRA Life Sciences and 0 mentions for Biotricity. ENDRA Life Sciences' average media sentiment score of 1.87 beat Biotricity's score of 0.00 indicating that ENDRA Life Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Biotricity	Neutral
ENDRA Life Sciences	Very Positive

3.9% of Biotricity shares are owned by institutional investors. Comparatively, 1.2% of ENDRA Life Sciences shares are owned by institutional investors. 1.6% of Biotricity shares are owned by company insiders. Comparatively, 10.0% of ENDRA Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Biotricity has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market. Comparatively, ENDRA Life Sciences has a beta of -0.05, indicating that its share price is 105% less volatile than the broader market.

ENDRA Life Sciences has lower revenue, but higher earnings than Biotricity. Biotricity is trading at a lower price-to-earnings ratio than ENDRA Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biotricity	$12.06M	0.21	-$14.09M	-$0.14	N/A
ENDRA Life Sciences	N/A	N/A	-$7.03M	-$6.38	N/A

ENDRA Life Sciences has a net margin of 0.00% compared to Biotricity's net margin of -80.42%. Biotricity's return on equity of 0.00% beat ENDRA Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biotricity	-80.42%	N/A	-188.47%
ENDRA Life Sciences	N/A	-246.34%	-150.81%

Summary

ENDRA Life Sciences beats Biotricity on 9 of the 15 factors compared between the two stocks.

How does Biotricity compare to enVVeno Medical?

enVVeno Medical (NASDAQ:NVNO) and Biotricity (NASDAQ:BTCY) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, valuation, risk and institutional ownership.

34.7% of enVVeno Medical shares are owned by institutional investors. Comparatively, 3.9% of Biotricity shares are owned by institutional investors. 15.0% of enVVeno Medical shares are owned by company insiders. Comparatively, 1.6% of Biotricity shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

enVVeno Medical has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market. Comparatively, Biotricity has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market.

enVVeno Medical has a net margin of 0.00% compared to Biotricity's net margin of -80.42%. Biotricity's return on equity of 0.00% beat enVVeno Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enVVeno Medical	N/A	-62.28%	-56.83%
Biotricity	-80.42%	N/A	-188.47%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enVVeno Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Biotricity	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, enVVeno Medical had 2 more articles in the media than Biotricity. MarketBeat recorded 2 mentions for enVVeno Medical and 0 mentions for Biotricity. enVVeno Medical's average media sentiment score of 0.47 beat Biotricity's score of 0.00 indicating that enVVeno Medical is being referred to more favorably in the media.

Company	Overall Sentiment
enVVeno Medical	Neutral
Biotricity	Neutral

Biotricity has higher revenue and earnings than enVVeno Medical. Biotricity is trading at a lower price-to-earnings ratio than enVVeno Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enVVeno Medical	N/A	N/A	-$19.47M	-$19.33	N/A
Biotricity	$12.06M	0.21	-$14.09M	-$0.14	N/A

Summary

enVVeno Medical beats Biotricity on 8 of the 14 factors compared between the two stocks.

How does Biotricity compare to IceCure Medical?

Biotricity (NASDAQ:BTCY) and IceCure Medical (NASDAQ:ICCM) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends and analyst recommendations.

Biotricity has a net margin of -80.42% compared to IceCure Medical's net margin of -427.67%. Biotricity's return on equity of 0.00% beat IceCure Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biotricity	-80.42%	N/A	-188.47%
IceCure Medical	-427.67%	-174.26%	-112.58%

Biotricity has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market. Comparatively, IceCure Medical has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market.

3.9% of Biotricity shares are owned by institutional investors. Comparatively, 0.6% of IceCure Medical shares are owned by institutional investors. 1.6% of Biotricity shares are owned by insiders. Comparatively, 2.4% of IceCure Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

IceCure Medical has a consensus price target of $52.50, indicating a potential upside of 2,182.61%. Given IceCure Medical's stronger consensus rating and higher probable upside, analysts clearly believe IceCure Medical is more favorable than Biotricity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biotricity	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
IceCure Medical	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Biotricity has higher revenue and earnings than IceCure Medical. Biotricity is trading at a lower price-to-earnings ratio than IceCure Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biotricity	$12.06M	0.21	-$14.09M	-$0.14	N/A
IceCure Medical	$3.95M	2.00	-$15.06M	-$8.52	N/A

In the previous week, IceCure Medical had 2 more articles in the media than Biotricity. MarketBeat recorded 2 mentions for IceCure Medical and 0 mentions for Biotricity. IceCure Medical's average media sentiment score of 0.28 beat Biotricity's score of 0.00 indicating that IceCure Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
Biotricity	Neutral
IceCure Medical	Neutral

Summary

Biotricity and IceCure Medical tied by winning 8 of the 16 factors compared between the two stocks.

How does Biotricity compare to Intelligent Bio Solutions?

Intelligent Bio Solutions (NASDAQ:INBS) and Biotricity (NASDAQ:BTCY) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, analyst recommendations, earnings and valuation.

Intelligent Bio Solutions has a beta of 4.21, meaning that its stock price is 321% more volatile than the broader market. Comparatively, Biotricity has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market.

In the previous week, Intelligent Bio Solutions had 2 more articles in the media than Biotricity. MarketBeat recorded 2 mentions for Intelligent Bio Solutions and 0 mentions for Biotricity. Intelligent Bio Solutions' average media sentiment score of 0.46 beat Biotricity's score of 0.00 indicating that Intelligent Bio Solutions is being referred to more favorably in the media.

Company	Overall Sentiment
Intelligent Bio Solutions	Neutral
Biotricity	Neutral

Biotricity has a net margin of -80.42% compared to Intelligent Bio Solutions' net margin of -294.88%. Biotricity's return on equity of 0.00% beat Intelligent Bio Solutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intelligent Bio Solutions	-294.88%	-175.35%	-91.25%
Biotricity	-80.42%	N/A	-188.47%

33.0% of Intelligent Bio Solutions shares are owned by institutional investors. Comparatively, 3.9% of Biotricity shares are owned by institutional investors. 1.3% of Intelligent Bio Solutions shares are owned by insiders. Comparatively, 1.6% of Biotricity shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intelligent Bio Solutions	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Biotricity	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Intelligent Bio Solutions has higher earnings, but lower revenue than Biotricity. Biotricity is trading at a lower price-to-earnings ratio than Intelligent Bio Solutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intelligent Bio Solutions	$4.22M	1.69	-$12.43M	-$9.02	N/A
Biotricity	$12.06M	0.21	-$14.09M	-$0.14	N/A

Summary

Intelligent Bio Solutions beats Biotricity on 8 of the 14 factors compared between the two stocks.

Get Biotricity News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BTCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BTCY vs. The Competition

Export

Metric	Biotricity	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.51M	$5.78B	$7.18B	$12.88B
Dividend Yield	N/A	1.75%	2.54%	11.27%
P/E Ratio	-0.11	25.92	273.17	25.45
Price / Sales	0.21	78.68	637.96	103.59
Price / Cash	N/A	33.69	28.74	36.03
Price / Book	-0.10	6.18	11.08	6.36
Net Income	-$14.09M	$149.94M	$3.48B	$349.79M
7 Day Performance	10.50%	-0.70%	0.21%	-0.48%
1 Month Performance	12.91%	5.99%	7.75%	4.17%
1 Year Performance	-77.00%	6.19%	24.68%	15.11%

Biotricity Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BTCY Biotricity	N/A	$0.12 flat	N/A	-77.0%	$2.51M	$12.06M	N/A	40	Gap Up
MBAI Check-Cap	0.7086 of 5 stars	$6.57 -3.1%	N/A	N/A	$9.33M	N/A	N/A	80
NDRA ENDRA Life Sciences	3.0656 of 5 stars	$5.40 -0.7%	$25.00 +363.0%	+22.5%	$8.16M	N/A	N/A	20	Positive News
NVNO enVVeno Medical	1.519 of 5 stars	$11.40 -0.6%	N/A	-61.6%	$7.97M	N/A	N/A	30
ICCM IceCure Medical	2.3611 of 5 stars	$2.29 flat	$52.50 +2,192.6%	-93.2%	$7.85M	$3.95M	N/A	60

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BTCY) was last updated on 8/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biotricity (BTCY) Competitors

BTCY vs. MBAI, NDRA, NVNO, ICCM, and INBS

How does Biotricity compare to Check-Cap?

Summary

How does Biotricity compare to ENDRA Life Sciences?

Summary

How does Biotricity compare to enVVeno Medical?

Summary

How does Biotricity compare to IceCure Medical?

Summary

How does Biotricity compare to Intelligent Bio Solutions?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BTCY vs. The Competition

Biotricity Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biotricity (BTCY) Competitors

BTCY vs. MBAI, NDRA, NVNO, ICCM, and INBS

How does Biotricity compare to Check-Cap?

Do analysts prefer BTCY or MBAI?

Does the media prefer BTCY or MBAI?

Which has more risk & volatility, BTCY or MBAI?

Which has better valuation & earnings, BTCY or MBAI?

Is BTCY or MBAI more profitable?

Do institutionals and insiders hold more shares of BTCY or MBAI?

Summary

How does Biotricity compare to ENDRA Life Sciences?

Do analysts rate BTCY or NDRA?

Does the media favor BTCY or NDRA?

Do institutionals and insiders have more ownership in BTCY or NDRA?

Which has more volatility and risk, BTCY or NDRA?

Which has stronger earnings and valuation, BTCY or NDRA?

Is BTCY or NDRA more profitable?

Summary

How does Biotricity compare to enVVeno Medical?

Do institutionals & insiders believe in NVNO or BTCY?

Which has more risk and volatility, NVNO or BTCY?

Is NVNO or BTCY more profitable?

Do analysts rate NVNO or BTCY?

Does the media favor NVNO or BTCY?

Which has stronger valuation & earnings, NVNO or BTCY?

Summary

How does Biotricity compare to IceCure Medical?

Is BTCY or ICCM more profitable?

Which has more risk & volatility, BTCY or ICCM?

Do insiders & institutionals believe in BTCY or ICCM?

Do analysts prefer BTCY or ICCM?

Which has better valuation and earnings, BTCY or ICCM?

Does the media refer more to BTCY or ICCM?

Summary

How does Biotricity compare to Intelligent Bio Solutions?

Which has more risk & volatility, INBS or BTCY?

Does the media prefer INBS or BTCY?

Is INBS or BTCY more profitable?

Do institutionals & insiders believe in INBS or BTCY?

Do analysts prefer INBS or BTCY?

Which has stronger valuation & earnings, INBS or BTCY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BTCY vs. The Competition

Biotricity Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools